Katherine A. Kong

2.8k total citations
28 papers, 906 citations indexed

About

Katherine A. Kong is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Katherine A. Kong has authored 28 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pathology and Forensic Medicine and 10 papers in Cancer Research. Recurrent topics in Katherine A. Kong's work include CAR-T cell therapy research (11 papers), Cancer Genomics and Diagnostics (10 papers) and Lymphoma Diagnosis and Treatment (10 papers). Katherine A. Kong is often cited by papers focused on CAR-T cell therapy research (11 papers), Cancer Genomics and Diagnostics (10 papers) and Lymphoma Diagnosis and Treatment (10 papers). Katherine A. Kong collaborates with scholars based in United States, France and Japan. Katherine A. Kong's co-authors include Malek Faham, Jianbiao Zheng, Martin Moorhead, Wyndham H. Wilson, David B. Miklos, François Pépin, Stefania Pittaluga, Catherine Lai, Mark Roschewski and Elaine S. Jaffe and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Katherine A. Kong

27 papers receiving 898 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katherine A. Kong United States	12	424	375	345	193	164	28	906
Caleb Ho United States	17	212 0.5×	411 1.1×	564 1.6×	874 4.5×	259 1.6×	35	1.6k
David Ghez France	21	327 0.8×	395 1.1×	39 0.1×	241 1.2×	275 1.7×	81	1.4k
Emanuele Marchi United Kingdom	15	87 0.2×	152 0.4×	88 0.3×	242 1.3×	100 0.6×	28	887
Polly R. Etkind United States	19	88 0.2×	221 0.6×	120 0.3×	548 2.8×	117 0.7×	30	1.2k
Misako Yajima Japan	15	223 0.5×	566 1.5×	87 0.3×	210 1.1×	50 0.3×	25	1.1k
Dai Iwakiri Japan	19	309 0.7×	955 2.5×	351 1.0×	578 3.0×	56 0.3×	26	1.8k
Tina Green United States	14	577 1.4×	419 1.1×	27 0.1×	199 1.0×	49 0.3×	31	1.3k
Roberta Guglielmino Italy	13	166 0.4×	174 0.5×	40 0.1×	178 0.9×	36 0.2×	23	687
Clas F. R. Källander Sweden	19	235 0.6×	326 0.9×	30 0.1×	208 1.1×	145 0.9×	50	1.1k
C A Heilman United States	16	137 0.3×	355 0.9×	100 0.3×	386 2.0×	40 0.2×	24	1.3k

Countries citing papers authored by Katherine A. Kong

Since Specialization

Citations

This map shows the geographic impact of Katherine A. Kong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine A. Kong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine A. Kong more than expected).

Fields of papers citing papers by Katherine A. Kong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine A. Kong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine A. Kong. The network helps show where Katherine A. Kong may publish in the future.

Co-authorship network of co-authors of Katherine A. Kong

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine A. Kong. A scholar is included among the top collaborators of Katherine A. Kong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine A. Kong. Katherine A. Kong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spiegel, Jay Y., Jean Oak, Anmol Goyal, et al.. (2024). CD19 Antigen Density Down-Regulation at Time of Progression in Large B-Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel. Transplantation and Cellular Therapy. 30(2). S204–S204.

Su, Yi‐Jiun, Mark Hamilton, Neha Agarwal, et al.. (2023). Post-CAR-T Minimal Residual Disease (MRD) Monitoring in Mantle Cell Lymphoma Enables Early Relapse Detection. Blood. 142(Supplement 1). 1673–1673. 1 indexed citations

Frank, Matthew J., Nasheed Hossain, Ali Bukhari, et al.. (2021). Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. Journal of Clinical Oncology. 39(27). 3034–3043. 87 indexed citations

Good, Zinaida, Jay Y. Spiegel, Bita Sahaf, et al.. (2019). Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel. Blood. 134(Supplement_1). 779–779. 4 indexed citations

Frank, Matthew J., Nasheed Hossain, Ali Bukhari, et al.. (2019). Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma. Blood. 134(Supplement_1). 884–884. 14 indexed citations

Oak, Jean, Jay Y. Spiegel, Bita Sahaf, et al.. (2018). Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy. Blood. 132(Supplement 1). 4656–4656. 9 indexed citations

Takezako, Naoki, Jianbiao Zheng, Martin Moorhead, et al.. (2017). Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Annals of Oncology. 28(10). 2503–2510. 33 indexed citations

Wolf, Jeffrey L., et al.. (2016). Next-Generation Sequencing Based Minimal Residual Disease Assessment in Peripheral Blood RNA from Multiple Myeloma Patients. Blood. 128(22). 3286–3286. 2 indexed citations

Susanibar-Adaniya, Sandra P., Victoria Carlton, Sharmilan Thanendrarajan, et al.. (2016). Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma. Blood. 128(22). 377–377. 1 indexed citations

10.

Herrera, Alex F., Haesook T. Kim, Katherine A. Kong, et al.. (2016). Next‐generation sequencing‐based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. British Journal of Haematology. 175(5). 841–850. 50 indexed citations

11.

Mannis, Gabriel N., Thomas Martin, Lloyd E. Damon, et al.. (2016). Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 22(6). 1030–1036. 9 indexed citations

12.

Oki, Yasuhiro, Sattva S. Neelapu, Michelle A. Fanale, et al.. (2015). Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next‐generation sequencing approach. British Journal of Haematology. 169(5). 689–693. 40 indexed citations

13.

Roschewski, Mark, Kieron Dunleavy, Stefania Pittaluga, et al.. (2015). Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. The Lancet Oncology. 16(5). 541–549. 307 indexed citations

14.

Zimmerman, Todd M., Kent A. Griffith, Jagoda Jasielec, et al.. (2015). Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).. Journal of Clinical Oncology. 33(15_suppl). 8510–8510. 10 indexed citations

15.

Logan, Aaron C., Malek Faham, Victoria Carlton, et al.. (2014). Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival. Biology of Blood and Marrow Transplantation. 20(9). 1307–1313. 101 indexed citations

16.

Roschewski, Mark, Stefania Pittaluga, Kieron Dunleavy, et al.. (2013). DNA Sequencing-Based Monitoring Of Serum Predicts Clinical Relapse Before CT Imaging in Diffuse Large B-Cell Lymphoma. Blood. 122(21). 1767–1767. 3 indexed citations

17.

Klinger, Mark, Katherine A. Kong, Martin Moorhead, et al.. (2013). Combining Next-Generation Sequencing and Immune Assays: A Novel Method for Identification of Antigen-Specific T Cells. PLoS ONE. 8(9). e74231–e74231. 29 indexed citations

18.

Leclercq, India, Nicolás Berthet, Christophe Batéjat, et al.. (2010). Use of consensus sequences for the design of high density resequencing microarrays: the influenza virus paradigm. BMC Genomics. 11(1). 586–586. 4 indexed citations

19.

Berthet, Nicolás, Anita Reinhardt, India Leclercq, et al.. (2008). Phi29 polymerase based random amplification of viral RNA as an alternative to random RT-PCR. BMC Molecular Biology. 9(1). 77–77. 66 indexed citations

20.

Berthet, Nicolás, Ingrid Filliol, Anita Reinhardt, et al.. (2007). Massively parallel pathogen identification using high‐density microarrays. Microbial Biotechnology. 1(1). 79–86. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact